A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)

Investigators are trying to find better treatments for people with HIV-1. In this clinical study, investigators want to see how well a new treatment called ISL+ULO, taken once a week, works compared to an existing treatment called BIC/FTC/TAF, which is taken every day. Investigators will check how many people still have a high level of the virus in their blood after 24 weeks. The investigators also want to understand if the new treatment, MK-8591B, is safe and how well people can handle it.

NCT Number	NCT06891066
Lead Sponsor	Merck Sharp & Dohme LLC
Conditions	Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Enrollment	150 participants
Start Date	2025-04-14
Primary Completion	2027-08-10 (estimated)
Study Completion	2031-09-30 (estimated)
Updated on ClinicalTrials.gov	2025-10-16